Ultralife Corporation (ULBI)
Pre-market:
| Previous close | 11.54 |
| Open | 11.37 |
| Bid | 11.63 x 100 |
| Ask | 11.80 x 100 |
| Day's range | 11.37 - 12.22 |
| 52-week range | 3.92 - 12.22 |
| Volume | |
| Avg. volume | 79,290 |
| Market cap | 192.659M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | 18.28 |
| EPS (TTM) | 0.64 |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeyUltralife Corporation (NASDAQ:ULBI) Q1 2024 Earnings Call Transcript
Ultralife Corporation (NASDAQ:ULBI) Q1 2024 Earnings Call Transcript April 27, 2024 Ultralife Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by. Welcome to the Ultralife Corporation First Quarter Conference Call. At this […]
- GuruFocus.com
Ultralife Corp (ULBI) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic Wins
Ultralife reports a robust 31.4% revenue increase and significant improvements in government defense sales and gross margins.
GlobeNewswireUltralife Corporation Reports First Quarter Results
NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quart
